Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

INSIDE INFORMATION ANNOUNCEMENT - PRELIMINARY RESULTS OF A PHASE I CLINICAL TRIAL OF JSKN003 IN AUSTRALIA FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED SOLID TUMORS 2023-11-16
INSIDE INFORMATION ANNOUNCEMENT - UPDATES IN RELATION TO A PHASE III CLINICAL TRIAL OF KN046 FOR THE TREATMENT OF ADVANCED PDAC 2023-11-14
VOLUNTARY ANNOUNCEMENT -UNUSUAL PRICE MOVEMENTS 2023-11-14
VOLUNTARY ANNOUNCEMENT - KN026 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA 2023-11-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023 2023-11-06
GRANT OF SHARE OPTIONS 2023-10-24
VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON KN046 AND KN026 PRESENTED AT ESMO CONGRESS 2023 2023-10-23
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023 2023-10-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023 2023-09-06
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023 2023-08-23

5 6 7 8 9 10 11